Bi‐allelic loss‐of‐function GALNT3 mutations alter FGF23 metabolism, resulting in hyperphosphatemia and causing familial tumoral calcinosis (FTC). Here, FGF23 is linked to thyroid cancer, nonmedullary, 2.